SimplyCast.com, a leading provider of interactive marketing software and services for organizations worldwide, is pleased to announce the launch of its survey marketing service.

Innovacorp has once again been named one of two finalists in the National Business Incubation Association (NBIA) Incubation Program of the Year - 2010 competition.

Immunovaccine Inc. (TSX-V: IMV) today announced that it has started screening patients for its Phase I clinical trial, investigating the company’s therapeutic cancer vaccine, DPX-0907, as a treatment for patients with advanced stage breast, ovarian and prostate cancer. The primary goal of the trial is to establish the safety of the vaccine candidate which includes the DepoVax™ delivery platform. Secondary goals include an evaluation of dosing and an assessment of immune response.

EastMed Inc., an Atlantic Canadian medical manufacturing company that caters specifically to women's health and wellness, now has national health coverage for the uresta® Continence Care product.

SimplyCast.com, a leading provider of multi-channel interactive marketing software and services, is pleased to announce the launch of the first and only 7-in-1 marketing platform in the world.

Innovacorp today, Mar. 9, announced Dan MacDonald is leaving his role as the organization’s president and CEO to pursue an opportunity in the private sector. The interim leader will be Stephen Hartlen, vice president with Innovacorp.

On February 9, 2010, more than 250 Nova Scotians celebrated innovation and entrepreneurship in the province at the World Trade and Convention Centre in downtown Halifax. That evening, Innovacorp announced Tether as the provincial winner of the I-3 Technology Start-Up Competition, and celebrated the 1st and 2nd place award winners from the competition's five provincial zones. Check out the evening's sights and sounds.

Tether from Halifax was awarded a $100,000 seed investment from Innovacorp to build on its early business success.

Innovascreen announces today an agreement with Saint Mary’s University to option the rights to a library of novel dacarbazine analogs, a promising class of alkylating agents similar to temozolomide, a first line therapy for an aggressive type of brain tumour known as glioblastoma. The option provides Innovascreen the rights to screen the library for lead compounds and conduct preclinical validation studies to determine safety and efficacy.

Innovacorp today announced the first and second place award winners in the provincial I-3 Technology Start-Up Competition, an innovative competition to identify and support high potential Nova Scotia knowledge-based businesses.